Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406051 | 0.91 | MTNR1B (0.47) | HTR2CDRD3HTR1AMTNR1BTRPV1 | |
| SCHEMBL6405785 | 0.82 | HTR2C (0.49) | HTR2CDRD3HTR1AMTNR1BSLC6A5 | |
| SCHEMBL6409507 | 0.81 | SLC6A5 (0.48) | MTNR1BSLC6A5HRH3 | |
| SCHEMBL6407049 | 0.80 | CNR1 (0.56) | HTR2CDRD3HTR1A | |
| SCHEMBL6407417 | 0.77 | HRH4 (0.52) | HTR2CDRD3HTR1A | |
| SCHEMBL6405025 | 0.75 | TRPV1 (0.60) | MTNR1BTRPV1HRH3 | |
| SCHEMBL6403218 | 0.74 | MTNR1B (0.50) | MTNR1BSLC6A5MTNR1A | |
| SCHEMBL6405838 | 0.74 | MTNR1B (0.58) | MTNR1BMTNR1A | |
| SCHEMBL6408320 | 0.74 | MTNR1B (0.45) | HTR2CDRD3HTR1AMTNR1BSLC6A5 | |
| SCHEMBL6409860 | 0.74 | HTR2C (0.48) | HTR2CDRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | HTR2C 8/4885DRD3 33/4885HTR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.